Welcome to our dedicated page for Taysha Gene Therapies SEC filings (Ticker: TSHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Taysha Gene Therapies, Inc. filings document regulatory disclosures for a Nasdaq-listed clinical-stage biotechnology company developing AAV-based gene therapies for severe monogenic CNS diseases. Its 8-K reports furnish financial results, business highlights, TSHA-102 clinical and regulatory updates, program-rights announcements, and exhibits tied to company press releases.
The filing record also includes proxy materials for annual stockholder meetings, director elections and voting matters, as well as material definitive agreement disclosures involving common-stock sales arrangements. Cover-page disclosures identify TSHA common stock, par value and Nasdaq listing status, while proxy filings provide formal governance and stockholder-meeting information.
Taysha Gene Therapies director John A. Stalfort III reported equity awards in the company’s common stock. He received 21,335 shares through a restricted stock unit award at a price of $0.00 per share. These RSUs vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to his continued service as a director.
He was also granted stock options for 42,671 shares of common stock at an exercise price of $5.97 per share, expiring on June 1, 2036. Following these awards, he holds 1,176,559 shares of common stock directly and 884,290 shares indirectly through the John A. Stalfort III 2018 Irrevocable Trust.
Taysha Gene Therapies director Phillip B. Donenberg reported equity compensation grants. He received 21,335 shares of Common Stock as a restricted stock unit award at no purchase price. These RSUs vest on the earlier of June 1, 2027 or the next annual stockholders meeting, if he continues serving as a director.
He was also granted a stock option covering 42,671 shares of Common Stock at an exercise price of $5.97 per share, expiring on June 1, 2036. Following these grants, he directly holds 241,289 shares of Common Stock.
Taysha Gene Therapies director Alison S. Long reported equity compensation awards. She received 21,335 shares of Common Stock as a restricted stock unit (RSU) award that will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, contingent on her continued board service.
She was also granted stock options covering 42,671 shares of Common Stock at an exercise price of $5.97 per share, expiring on June 1, 2036. Following these awards, she directly holds 127,178 shares of Common Stock and 42,671 stock options.
Taysha Gene Therapies director Laura Sepp-Lorenzino reported equity awards consisting of restricted stock units and stock options. She received 21,335 shares of Common Stock as a restricted stock unit (RSU) award, which will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to her continued service as a director. She was also granted a stock option for 42,671 shares of Common Stock at an exercise price of $5.97 per share, expiring on June 1, 2036. Following these awards, she directly holds 127,178 shares of Common Stock and 42,671 options.
Taysha Gene Therapies, Inc. reported voting results from its 2026 annual meeting of stockholders. Of 287,341,999 shares outstanding on the record date, 243,857,812 shares, or about 84.86%, were present or represented by proxy, indicating strong participation.
Stockholders elected Sean P. Nolan and Laura Sepp-Lorenzino, Ph.D. as directors to serve until the 2029 annual meeting. They also ratified Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026, with 243,814,085 votes in favor.
On a non-binding basis, stockholders approved the compensation of the named executive officers and expressed a preference to hold future advisory votes on executive pay every year. The company plans to hold these say-on-pay votes annually unless the board later determines a different frequency is in stockholders’ best interests.
Taysha Gene Therapies reported that Vestal Point Capital, LP and Ryan Wilder beneficially hold 18,000,000 shares of common stock, representing 6.3% of the class based on 287,269,885 shares outstanding as of March 19, 2026.
The ownership is reflected as shared voting and dispositive power over the 18,000,000 shares. The filing is an amendment to a Schedule 13G, signed by Ryan Wilder on May 15, 2026.
Taysha Gene Therapies reports beneficial ownership disclosure by RTW Investments and Roderick Wong. The Reporting Persons state shared voting and dispositive power over 20,689,084 shares, representing 7.0% of the class based on 287,269,885 shares outstanding as of March 19, 2026. The amounts "assume the exercise of Warrants held by the Reporting Persons to purchase 7,008,836 Shares." The filing identifies the Reporting Persons' business address and notes the RTW Funds hold the economic right to dividends and sale proceeds.
Taysha Gene Therapies reported a wider quarterly loss as it increased investment in gene therapy programs and collaboration revenue ended. For the three months ended March 31, 2026, revenue was $0 compared with $2.3 million a year earlier, when Astellas research revenue was recognized.
Research and development expense rose to $33.8 million from $15.6 million, and general and administrative expense increased to $9.7 million from $8.2 million, driving a net loss of $42.4 million versus $21.5 million. Operating cash outflow was $40.9 million. Cash and cash equivalents were $276.6 million, with total cash, cash equivalents and restricted cash of $279.3 million and total assets of $300.4 million. Management believes this cash will fund planned operations for at least twelve months. The company also carries a $50.0 million Trinity term loan measured at fair value and had an accumulated deficit of $753.7 million.
Taysha Gene Therapies reported first quarter 2026 results and progress on its Rett syndrome gene therapy TSHA-102. The company reaffirmed FDA alignment on its BLA pathway, including pivotal REVEAL trial design, endpoints and the potential to file based on a six-month interim analysis.
Research and development expenses were $33.8 million, up from $15.6 million a year earlier, reflecting BLA-enabling PPQ manufacturing and higher clinical spending on the REVEAL and ASPIRE trials. General and administrative expenses were $9.7 million, compared with $8.2 million.
Taysha reported a net loss of $42.4 million, or $0.12 per share, versus a $21.5 million loss, or $0.08 per share, in the prior-year quarter. The company ended March 31, 2026 with $276.6 million in cash and cash equivalents and expects this to fund planned operating expenses into 2028.